Twist Bioscience Corp (TWST) Form 424B5 — Aug 4, 2026

$TWSTForm 424B5Filed Aug 4, 2026, 5:19 PM ET0001104659-26-090503Original filing

Twist Bioscience Corporation launched a $250.0 million underwritten offering of its common stock via a preliminary prospectus supplement dated August 4, 2026, with a 30-day underwriters' option to purchase up to $37.5 million of additional shares. The stock last traded at $101.06 on Nasdaq (TWST) on August 3, 2026, implying roughly 4% dilution to the 62.7 million shares outstanding before the greenshoe. Goldman Sachs, William Blair, Leerink Partners and Guggenheim Securities are running the deal.

Key figures

Eps: -$0.56 per diluted share (Q3 FY2026)
Revenue: $118.4 million (Q3 FY2026, quarter ended June 30, 2026)
Net Income: -$35.1 million (Q3 FY2026 net loss)
Gross Proceeds: $250.0 million aggregate offering size (before underwriting discounts and expenses)
Shares Outstanding: 62674150
Greenshoe option: $37.5 million of additional shares, 30-day underwriters' option
Lockup period days: 60
Atm capacity remaining: ~$200.0 million under Sales Agreement with TD Securities (no shares sold to date)
Adjusted ebitda q3 fy2026: -$11.3 million
Estimated dilution percent: ~4% before greenshoe (~4.5% if fully exercised), based on $101.06 reference price
Last sale price aug 3 2026: $101.06
Invenra share issuance allowance: up to $5.0 million of shares issuable to Invenra Inc. under the February 11, 2026 License Agreement
Net tangible book value jun 30 2026: $350.8 million, or $5.60 per share

Price after filing

1 day: +25.9%7 days: +34.8%30 days: +43.4%

Close on the filing date to close N calendar days later (from $91.33). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.